Maraviroc Oral Solution and Nevirapine Extended Release

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with nevirapine does not appear to significantly alter the plasma concentrations of maraviroc. In 12 study subjects, nevirapine (200 mg twice a day plus lamivudine 150 mg twice a day and tenofovir 300 mg once a day) increased the peak plasma concentration (Cmax) of a single 300 mg dose of maraviroc by 54% but did not affect the overall systemic exposure relative to historical data. No dosage adjustment of maraviroc is necessary when coadministered with nevirapine in the absence of concomitant potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, delavirdine, clarithromycin, telithromycin, nefazodone, or protease inhibitors.

Maraviroc Oral Solution

Generic Name: maraviroc

Brand name: Selzentry

Synonyms: Maraviroc

What is Maraviroc Oral Solution?

Nevirapine Extended Release

Generic Name: nevirapine

Brand name: Viramune, Viramune XR

Synonyms: Nevirapine

What is Nevirapine Extended Release?